Geographically, North America dominated the DVT screening and treatment devices market, with approximately half of the world’s procedures being done in the U.S. because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have the fastest growth, owing to a rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and the growing medical tourism industry in developing nations such as China, and India in this region. Among all the treatments, imaging modalities has the highest market share in the DVT screening and treatment devices market.
This report identifies the DVT screening and treatment devices market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the DVT screening and treatment devices market.
This report segments the DVT screening and treatment devices market on the basis of treatment, and regional market as follows:
The report has focused study on DVT screening and treatment devices market by basis of treatment such as: Imaging Modalities, Intravascular Ultrasound, Venous Stenting, and Compression Stockings, and Others
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the DVT screening and treatment devices market. Some of the major companies’ profiles in detail are as follows:
F. Hoffmann-La Roche Ltd.
Generex Biotechnology Corporation
Laboratorios Farmaceuticos Rovi, S.A.
Pharmathen Pharmaceuticals S.A.
Bristol-Myers Squibb Company
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. DVT Screening and Treatment Devices Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. DVT Screening and Treatment Devices Market– Forces
4.1.1. Development of efficient and advance technology
4.1.2. Growing incidences of Deep Vein Thrombosis (DVT)
4.2.1. Higher cost of research and development
4.3.1. Emerging economies
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. DVT Screening and Treatment Devices Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. DVT Screening and Treatment Devices Market, By Treatment
6.1. Imaging Modalities
6.2. Intravascular Ultrasound
6.3. Venous Stenting
6.4. Compression Stockings
7. DVT Screening and Treatment Devices Market, By Geography
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.4. Rest of the World (RoW)
7.4.2. Rest of RoW
8. DVT Screening and Treatment Devices – Entropy
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. F. Hoffmann-La Roche Ltd.
9.2. Generex Biotechnology Corporation
9.3. Laboratorios Farmaceuticos Rovi, S.A.
9.4. Pharmathen Pharmaceuticals S.A.
9.5. Bristol-Myers Squibb Company
9.6. 3SBio Inc.
9.7. Dupont Pharm Co
9.8. Wockhardt Ltd
9.9. Bayer AG
9.10. Pfizer Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10.3. Research Methodology
10.5. Compilation of Expert Insights